צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים: BD (BDX)

Balanced global sales provide Becton Dickinson & Co (BDX) with steady cash flows. The non-cyclical nature of the business ensures high macro-resilience even during crises. The quarterly EPS growth rate reflects the issuer's real economics, where the value of 47.30 characterizes this level. Stable global sales of mass-market disposable syringes and blood collection systems confirm the company's fundamental reliability.

Quarterly earnings per share (EPS) growth reflects the monetization efficiency of medical consumables and laboratory equipment at Becton Dickinson & Co (BDX). This metric measures net income per share dynamics, filtering out short-term market noise. Comparing quarterly EPS reveals the true fundamental resilience of the business. This indicator demonstrates the company's ability to convert syringe and catheter sales into actual shareholder returns. Stable growth confirms operational profitability and the issuer's low vulnerability.